GLP-1 Weight Loss Statistics: Published Clinical Trial Results

GLP-1 medications (which mimic a natural gut hormone that controls appetite and blood sugar) have revolutionized medical weight loss treatment. This page compiles the latest clinical trial data, real-world outcomes, and research findings on semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and related medications.

Semaglutide Clinical Trial Results

The STEP (Semaglutide Treatment Effect in People with Obesity) trials established semaglutide 2.4mg as a breakthrough weight loss medication. STEP 1 showed participants lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo. STEP 2 demonstrated 9.6% weight loss in patients with type 2 diabetes. STEP 3 combined with intensive behavioral therapy achieved 16% average weight loss. STEP 4 showed that discontinuing semaglutide led to weight regain, highlighting the importance of ongoing treatment.

• STEP 1: 14.9% average weight loss (vs 2.4% placebo)
• STEP 2: 9.6% weight loss in diabetic patients
• STEP 3: 16% with intensive behavioral therapy
• 86.4% of participants achieved ≥5% weight loss
• 69.1% achieved ≥10% weight loss
• 50.5% achieved ≥15% weight loss

Tirzepatide Clinical Trial Results

The SURMOUNT trials demonstrated tirzepatide's superior results. Tirzepatide works by mimicking two natural gut hormones instead of one. SURMOUNT-1 showed weight loss of 15% (5mg), 19.5% (10mg), and 20.9% (15mg) at 72 weeks. Over half of participants on the highest dose achieved 20% or more weight loss, approaching surgical-level results. SURMOUNT-2 confirmed 12-15% weight loss in patients with type 2 diabetes.

• SURMOUNT-1: Up to 20.9% weight loss (15mg dose)
• SURMOUNT-2: 12-15% in diabetic patients
• 57% achieved ≥20% weight loss on 15mg
• 91% achieved ≥5% weight loss
• 37% achieved ≥25% weight loss
• Weight loss comparable to bariatric surgery outcomes

Cardiovascular Benefits

The SELECT trial demonstrated a 20% reduction in major heart events (heart attack, stroke, and death from heart disease) in overweight patients without diabetes but with existing heart disease. This led to an expanded FDA approval for heart risk reduction. This was a landmark finding that GLP-1 medications protect the heart beyond just their weight loss effects.

• 20% reduction in major heart events (heart attack, stroke, cardiovascular death)
• 18% reduction in death from heart disease
• 28% reduction in heart failure hospitalization
• Benefits seen regardless of starting weight
• Risk reduction begins within 8-12 weeks of treatment

Real-World Outcomes vs. Clinical Trials

Real-world studies show slightly lower but still significant weight loss compared to controlled trials. A 2023 retrospective analysis of 3,256 patients on semaglutide showed 10-12% average weight loss at 12 months in clinical practice settings. Factors affecting real-world outcomes include medication adherence, insurance coverage gaps, and variable access to supportive care.

• Real-world weight loss: 10-12% at 12 months
• Adherence rates: 60-70% at 12 months
• Insurance coverage remains a significant barrier
• Best outcomes achieved with comprehensive, physician-led care
• Behavioral support improves long-term maintenance

Safety & Side Effect Profile

The most common side effects are digestive, occurring in 40-70% of patients but typically mild and temporary. Nausea affects 40-50% initially but decreases over time. Serious side effects are rare but include a small risk of pancreatitis (inflammation of the pancreas, 0.1-0.3%) and gallbladder problems. Starting at a low dose and increasing gradually, with physician monitoring, significantly reduces side effects.

• Digestive side effects: 40-70% (mostly mild, temporary)
• Nausea: 40-50% initially, decreasing over weeks
• Pancreatitis (pancreas inflammation) risk: 0.1-0.3%
• Gallbladder events: 1-2%
• Discontinuation due to side effects: 4-7%